Related references
Note: Only part of the references are listed.Documenting the Benefits and Cost Savings of a Large Multistate Cancer Pathway Program From a Payer's Perspective
Eugene D. Kreys et al.
JOURNAL OF ONCOLOGY PRACTICE (2013)
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M. Aapro et al.
ANNALS OF ONCOLOGY (2012)
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
Swu-Jane Lin et al.
BMC HEALTH SERVICES RESEARCH (2012)
The Effects of Clinical Pathways on Professional Practice, Patient Outcomes, Length of Stay, and Hospital Costs: Cochrane Systematic Review and Meta-Analysis
Thomas Rotter et al.
EVALUATION & THE HEALTH PROFESSIONS (2012)
Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes
Arnold L. Potosky et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy
Suja S. Rajan et al.
MEDICAL CARE (2011)
Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
Thomas A. Burke et al.
SUPPORTIVE CARE IN CANCER (2011)
Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications
Pere Gascon
ONCOLOGIST (2008)
Step by step development of clinical care pathways for older cancer patients, Necessary or desirable?
Maruscha de Vries et al.
EUROPEAN JOURNAL OF CANCER (2007)
Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations
Karin Jordan et al.
ONCOLOGIST (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
James R. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials
OAC Clark et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
V Caggiano et al.
CANCER (2005)
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer trial with erythropoietin terminated unexpectedly
B Leyland-Jones
LANCET ONCOLOGY (2003)
Targeted filgrastim support in patients with early-stage breast carcinoma - Toward the implementation of a risk model
E Rivera et al.
CANCER (2003)
Share Paper
